Business Context and Reporting Period
Cytosorbents Corporation filed a Form 8-K Current Report on December 21, 2017. The filing reports a regulatory milestone regarding the Company's REFRESH 2 Investigational Device Exemption (IDE) application.
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The material event reported is the U.S. Food and Drug Administration (FDA) granting approval of the REFRESH 2 IDE application. This approval is subject to conditions requiring clarifications and changes to the patient consent form and the Instructions for Use document.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary beyond the regulatory update. No specific risks or contingencies are detailed in this report, other than the conditional nature of the FDA approval requiring document revisions.
Investor Verification Checklist
- Verify the specific conditions imposed by the FDA regarding the patient consent form and Instructions for Use.
- Review the full text of the press release filed as Exhibit 99.1 for additional details on the REFRESH 2 study.
- Confirm the timeline for implementing the required document changes to proceed with the study.